Skip to main content

Cidara Therapeutics, Inc.

CDTXDelisted Jan 7, 2026
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001610618

Cidara Therapeutics, Inc. was delisted on Jan 7, 2026; its insiders filed their last Form 4 on Jan 9, 2026; 255 institutions reported holding it in 13F filings for Q4 2025, worth $7.36B in total; 3 superinvestors held it, including Maverick Capital and Soros Fund Management.

Q2 2021 vs. Q1 2021

How the institutions holding Cidara Therapeutics, Inc. changed between Q1 2021 and Q2 2021.

All holders in Q2 2021All holders in Q1 2021

13F holders of CDTX: Q1 2021 compared with Q2 2021
MeasureQ1 2021Q2 2021Change
Holders6255−7
Shares21.3M20.0M−1.25M (−5.9%)
Value$56.6M$40.5M−$16.1M (−28.5%)

New holders (14)

Institutions that held Cidara Therapeutics, Inc. at the end of Q2 2021 but not at the end of Q1 2021.

Institutions new to CDTX in Q2 2021
InstitutionSharesValue% of portfolio
Stonepine Capital Management, LLC1,211,286$2.45M1.28%
Tibra Equities Europe Ltd174,900$353.0K0.11%
Ergoteles LLC163,000$329.0K0.01%
HRT Financial LP102,445$206.0K0.00%
Opaleye Management Inc.73,351$148.0K0.02%
Parametric Portfolio Associates LLC34,001$69.0K0.00%
ExodusPoint Capital Management, LP25,522$52.0K0.00%
XTX Topco Ltd25,971$52.0K0.02%
Pitcairn Co23,161$47.0K0.00%
LMR Partners LLP10,852$22.0K0.00%
Advisor Group Holdings, Inc.10,000$20.0K0.00%
Optiver Holding B.V.5,090$10.0K0.00%
UBS Asset Management Americas Inc2,927$5.91K0.00%
Isthmus Partners, LLC2,000$4.00K0.00%

Sold out (21)

Institutions that held Cidara Therapeutics, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.